Riximyo Европска Унија - Хрватски - EMA (European Medicines Agency)

riximyo

sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastična sredstva - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. postoje samo ograničeni podaci o učinkovitosti i sigurnosti bolesnika prethodno liječenih monoklonsko antitijelo, uključujući rituksimab ili bolesne, vatrostalne standardnim tretmanima na prethodnu rituksimab + kemoterapija. cm. odjeljak 5. 1 za daljnje informacije. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimab je pokazala da smanjuje brzinu progresije oštećenja zglobova kao što se mjeri x-ray i poboljšati fizičku funkciju, prilikom raspoređivanja u kombinaciji s metotreksatom. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Rixathon Европска Унија - Хрватски - EMA (European Medicines Agency)

rixathon

sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis; microscopic polyangiitis; pemphigus - antineoplastična sredstva - rixathon is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)rixathon is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. rixathon maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. rixathon monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. rixathon is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. rixathon in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). kronične limfocitne leukemije (ХЛЛ)rixathon u kombinaciji s kemoterapijom što je prikazano za obradu bolesnika prethodno liječenih liječenje i relapsed/тугоплавким kroničnim лимфоцитарным. postoje samo ograničeni podaci o učinkovitosti i sigurnosti bolesnika prethodno liječenih monoklonsko antitijelo, uključujući rituksimab ili bolesne, vatrostalne standardnim tretmanima na prethodnu rituksimab + kemoterapija. cm. odjeljak 5. 1 za daljnje informacije. reumatoidni arthritisrixathon u kombinaciji s metotreksatom prikazana za liječenje odraslih bolesnika s teškim aktivnim reumatoidnim artritisom, koji su imali neadekvatan odgovor ili netoleranciju drugih bolesti дорабатывая anti-reumatskih lijekovi (dmards), uključujući jedan ili više faktora nekroze tumora (tnf) inhibitor terapija. rituksimab je pokazala da smanjuje brzinu progresije oštećenja zglobova kao što se mjeri x-ray i poboljšati fizičku funkciju, prilikom raspoređivanja u kombinaciji s metotreksatom. granulomatosis with polyangiitis and microscopic polyangiitisrixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). rixathon, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisrixathon is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

GAZYVARO 1000mg/40ml Koncentrat za rastvor za infuziju Црна Гора - Хрватски - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

gazyvaro 1000mg/40ml koncentrat za rastvor za infuziju

"hoffmann-la roche ltd" d.s.d. podgorica - obinutuzumab - koncentrat za rastvor za infuziju - 1000mg/40ml

Tepkinly Европска Унија - Хрватски - EMA (European Medicines Agency)

tepkinly

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Profender Европска Унија - Хрватски - EMA (European Medicines Agency)

profender

vetoquinol s.a. - emodepside, празиквантел - antiparazitski proizvodi, insekticidi i repelenti - dogs; cats - catsfor mačke pate od ili sklone, mješoviti parazitskih infekcija uzrokovanih okruglih crva i traka crva od sljedećih vrsta:oblići (nematoda)Тохосага cati (i kao odrastao, nezreo odrasla osoba, Л4 i Л3);Тохосага cati (Л3 ličinke) – liječenje ферзей u kasnijoj trudnoći, kako bi se spriječilo лактогенное prijenos potomstvo;toxascaris leonina ograničeno (odrastao, nezreo odrasla osoba i Л4);skakavci ancylostoma tubaeforme (i kao odrastao, nezreo odrasla osoba i Л4). traka crvi (цестоды)dipylidium сатпит (odrasle zrele i nezrele odrasle osobe);таета taeniaeformis (za odrasle);эхинококк multilocularis (odrasla osoba). lungwormsaelurostrongylus abstrusus (za odrasle). dogsfor psi koji pate od ili sklone, mješoviti parazitskih infekcija uzrokovanih okruglih crva i traka crva od sljedećih vrsta:oblići (nematoda):Тохосага canis (i kao odrastao, nezreo odrasla osoba, Л4 i Л3);toxascaris leonina ograničeno (odrastao, nezreo odrasla osoba i Л4);ancylostoma сатпит (odrasle zrele i nezrele odrasle osobe);uncinaria stenocephala (odrasle zrele i nezrele odrasle osobe);власоглавы vulpis (i kao odrastao, nezreo odrasla osoba i Л4);traka (цестоды):dipylidium сатпит;таета spp. ;Эхинококк multilocularis (odrasli i nezreli);эхинококк granulosus (odrasle zrele i nezrele).